The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2017 | Why should elderly AML patients take part in clinical trials?
Mhairi Copland, PhD, MB, ChB, MRCP, FRCPath, from the University of Glasgow, Glasgow, UK, discusses why elderly acute myeloid leukemia (AML) patients should be encouraged to participate in clinical trials at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. She speaks about the low proportion of patients over 75 who take part in clinical trials, and emphasizes the need to include these patients if new treatments are to be developed.
